Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy

OBJECTIVE: Immunogenicity and safety following receipt of the standard SARS–CoV‐2 vaccination regimen in patients with immune‐mediated inflammatory diseases (IMIDs) are poorly characterized, and data after receipt of the third vaccine dose are lacking. The aim of the study was to evaluate serologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Syversen, Silje W., Jyssum, Ingrid, Tveter, Anne T., Tran, Trung T., Sexton, Joseph, Provan, Sella A., Mjaaland, Siri, Warren, David J., Kvien, Tore K., Grødeland, Gunnveig, Nissen‐Meyer, Lise S. H., Ricanek, Petr, Chopra, Adity, Andersson, Ane M., Kro, Grete B., Jahnsen, Jørgen, Munthe, Ludvig A., Haavardsholm, Espen A., Vaage, John T., Lund‐Johansen, Fridtjof, Jørgensen, Kristin K., Goll, Guro L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
COVID‐19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347774/
https://www.ncbi.nlm.nih.gov/pubmed/35507355
http://dx.doi.org/10.1002/art.42153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347774/
https://www.ncbi.nlm.nih.gov/pubmed/35507355
http://dx.doi.org/10.1002/art.42153

Ejemplares similares